Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19
Latest Information Update: 22 Sep 2021
At a glance
- Drugs Artesunate/amodiaquine (Primary) ; Artesunate/pyronaridine (Primary) ; Daclatasvir/sofosbuvir (Primary) ; Favipiravir (Primary) ; Nitazoxanide (Primary) ; Paracetamol
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Sponsors Shin Poong Pharmaceutical
- 16 Sep 2021 Status changed from recruiting to completed.
- 17 Dec 2020 Planned End Date changed from 1 Jan 2021 to 1 Oct 2021.
- 17 Dec 2020 Planned primary completion date changed from 1 Dec 2020 to 1 Jun 2021.